A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/08 → 7/31/14

Funding

  • Novartis (domestic): $170,847.00